P.010 Efficacy, Safety, and Tolerability of Ubrogepant for the Acute Treatment of Migraine: A Single-Attack Phase 3 Study, ACHIEVE II
Canadian Journal of Neurological Sciences - United Kingdom
doi 10.1017/cjn.2019.111
Full Text
Open PDFAbstract
Available in full text
Date
June 1, 2019
Authors
Publisher
Cambridge University Press (CUP)